Amyotrophic Lateral Sclerosis (ALS)

MDA Scientific Conference To Emphasize Therapy Development

The Muscular Dystrophy Association’s annual conference being held in Washington, D.C., on April 21-24, 2013, is centered on the theme Therapy Development for Neuromuscular Diseases: Translating Hope into Promise.

MDA and ALS TDI: Partnership Extended Through 2013

MDA and the nonprofit biotech ALS Therapy Development Institute (ALS TDI) have extended their strategic research partnership through 2013. With the extension comes a $3.2 million MDA grant to help support the nonprofit biotech's continued progress toward developing treatments for amyotrophic lateral sclerosis (ALS).

FDA Approves ALS Stem Cell Trial

Maryland biotherapeutics company Neuralstem today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to conduct a phase 2 clinical trial to test its NSI-566 neural stem cells in people with amyotrophic lateral sclerosis (ALS).

SMA Research Briefs: Testing Drugs from Other Diseases

In the search for therapies for spinal muscular atrophy (SMA), researchers are testing two drugs with connections to other neuromuscular disorders: riluzole, which is approved for use in amyotrophic lateral sclerosis (ALS); and tirasemtiv, which is already in testing for ALS and

Study Finds that Cognitive Status Predicts Functional Decline in ALS

The presence of cognitive impairment within the first year after a diagnosis of amyotrophic lateral sclerosis (ALS) may be associated with more rapid decline in muscle function, a team of researchers in Ireland has reported. Conversely, the absence of cognitive impairment within the first year appears to be associated with slower rates of functional decline.

Survey Open for People with ALS

An online survey about ALS symptoms, now open to people with amyotrophic lateral sclerosis (ALS), is being conducted by the Neurological Clinical Research Institute at Massachusetts General Hospital (MGH) in Boston. The site is one of five in MDA's ALS Clinical Research Network.

ALS Research Briefs: Role of Astrocytes in ALS

Scientists continue to work at uncovering the biological mechanisms underlying amyotrophic lateral sclerosis (ALS). One area of intense study involves the potential role of central nervous system support cells called astrocytes

Government Funding for NMD Research Largely Spared in Continuing Resolution

The news is generally favorable for many important government-funded neuromuscular disease research projects, in the wake of Congress’ recent passage of a continuing resolution funding the government through the end of September. 

Most government operations, except those funded through the full-year appropriations bills, will be maintained at essentially the same level as fiscal year (FY) 2012. (The government's fiscal year begins on Oct. 1 and ends on Sept. 30 of the following year.)

MDA and ALSA Urge FDA to Take Action on Groundbreaking ALS Hearing

The Muscular Dystrophy Association and The ALS Association (ALSA) submitted a joint comment to the U.S. Food and Drug Administration (FDA) today, commending and thanking the agency for convening its first-ever ALS public hearing on Feb.

ALS Research Briefs: Rasagiline and NurOwn

The latest advances in brain and central nervous system research were discussed at the 65th annual meeting of the American Academy of Neurology, held in San Diego, March 16-23, 2013.